免疫校正抗体疗法开发商Autoimmunity BioSolutions获得100万美元种子轮融资-动脉网

Autoimmunity BioSolutions Expands Seed Funding Round and Deepens Family Office Participation

CISION 等信源发布 2026-05-13 21:15



可切换为仅中文







New Capital Positions ABS to Reach Key Clinical Milestones and Advance Its Immuno-Corrective Autoimmune Therapy Platform

新资本助力ABS达成关键临床里程碑，推进其免疫矫正自身免疫治疗平台的发展

HOUSTON

休斯顿

，

May 13, 2026

2026年5月13日

/PRNewswire/ --

Autoimmunity BioSolutions (ABS)

自身免疫生物解决方案 (ABS)

, a biotechnology company developing a personalized, genetically-guided immuno-corrective therapy designed to normalize elevated levels of soluble IL7 receptor (sIL7R), today announced the close of a $1M seed extension financing round, bringing total seed capital raised to $3.1 million. The round was anchored by lead investor Eos BioInnovation and a select group of family offices whose long-term investment orientation reflects strong conviction in ABS's differentiated scientific platform and its potential to transform outcomes for the millions of autoimmune patients inadequately served by current therapies..

，一家开发生物技术公司，专注于开发一种个性化的、基因指导的免疫矫正疗法，旨在使可溶性IL7受体（sIL7R）的水平恢复正常，今天宣布完成了100万美元的种子扩展融资轮，使得种子轮融资总额达到310万美元。本轮融资由主要投资者Eos BioInnovation和一些家族办公室牵头，这些家族办公室的长期投资方向反映了对ABS公司差异化科学平台及其为数百万未能从现有疗法中获益的自身免疫病患者带来变革潜力的高度信任。

The round includes continued participation from existing investors EOS BioInnovation, Independent Capital and Elmstead Partners, reflecting strong ongoing confidence in the ABS platform. ABS also welcomes NewTech Investment Holdings to the round as a new family office investor. Their participation anchors the $1M seed extension..

本轮融资包括现有投资者EOS BioInnovation、Independent Capital和Elmstead Partners的持续参与，反映出对ABS平台的强烈持续信心。ABS还欢迎NewTech Investment Holdings作为新的家族办公室投资者加入本轮融资。他们的参与为100万美元的种子扩展轮融资奠定了基础。

'We are grateful for the continued support of our family office partners, whose participation in this seed extension reflects shared belief in the transformative potential of our platform,' said Eugene Williams, MBA, Chief Executive Officer, Autoimmunity BioSolutions. 'With the participation of seasoned investors who understand the pace and promise of life sciences innovation, we are well-positioned to deploy this capital with purpose, completing important animal model work and patient bio-sample analyses in our lead indication of Rheumatoid Arthritis, building on the compelling scientific momentum already underway at ABS.'.

“我们感谢家族办公室合作伙伴的持续支持，他们参与此次种子轮扩展，反映了对我们平台变革潜力的共同信念，” 自身免疫生物解决方案公司首席执行官尤金·威廉姆斯（Eugene Williams）表示，“在深谙生命科学创新节奏与前景的资深投资者的参与下，我们将能够有针对性地利用这笔资金，在我们的主要适应症类风湿性关节炎领域完成重要的动物模型研究和患者生物样本分析，进一步推动ABS目前已取得令人信服的科学进展。”

Advancing a Genetically Targeted Approach to Autoimmune Disease

推进针对自身免疫性疾病的基因靶向方法

ABS's scientific team has identified a highly prevalent SNP, estimated to be present in roughly 50% of the overall population, which causes a 2–3-fold increase in circulating sIL7R. Elevated sIL7R has been repeatedly shown in scientific evidence to contribute to greater disease severity, increased disease progression, and reduced response to standard-of-care therapies across multiple autoimmune indications, including rheumatoid arthritis (RA), lupus nephritis (LN), and type 1 diabetes (T1D)..

ABS的科学团队已经识别出一种高度流行的单核苷酸多态性（SNP），据估计大约50%的总人口携带这种基因变异，它会导致循环中的可溶性IL-7受体（sIL7R）增加2到3倍。大量科学证据反复表明，sIL7R水平升高会加剧疾病严重程度、加速疾病进展，并降低多种自身免疫性疾病对标准治疗的反应，这些疾病包括类风湿关节炎（RA）、狼疮性肾炎（LN）和1型糖尿病（T1D）。

About Autoimmunity BioSolutions (ABS)

关于自身免疫生物解决方案（ABS）

Autoimmunity BioSolutions (ABS) is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or 'correct' elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease. This therapy targets a genetically defined subpopulation of autoimmune disease patients marked by a highly prevalent genetic variant (SNP) that elevates the expression of sIL7R and is associated with greater severity of disease, increased progression of disease, and poor response to current treatments.

自体免疫生物解决方案公司（ABS）正在开创一种个性化的、基因指导的免疫矫正疗法，旨在使可溶性IL7受体（sIL7R）的水平正常化或“纠正”，这是自身免疫疾病治疗反应不佳的根本驱动因素。该疗法针对一个由高度普遍的基因变异（SNP）所定义的自身免疫疾病患者亚群，这种基因变异会提高sIL7R的表达，并与更严重的病情、更快的疾病进展以及对现有治疗的不良反应相关。

This immuno-corrective approach of targeting sIL7R in a genetic population is highly differentiated from current standards of care that rely on immunosuppressive mechanisms and has broad potential to enhance response to standards of care in the refractory population with elevated sIL7R across numerous autoimmune diseases.

这种针对遗传群体中sIL7R的免疫校正方法与当前依赖免疫抑制机制的护理标准高度差异化，并且在众多自身免疫疾病中，对于sIL7R升高、对标准治疗无反应的群体，具有广泛潜力来增强其对标准治疗的反应。

For more information, visit .

欲了解更多信息，请访问。

www.abstherapeutics.com

or follow us on

或关注我们

领英

。

For investor inquiries, please contact:

投资者咨询，请联系：

Jen Beachell

珍·比奇尔